Skip to main content

Table 3 38G model performance compared to CAPRA-S for association with BCR in the validation cohort (n = 423)

From: A 38-gene model comprised of key TET2-associated genes shows additive utility to high-risk prostate cancer cases in the prognostication of biochemical recurrence

  Sensitivity Specificity PPV NPV
Overall BCR
38G 81.4 36.33 15.02 93.39
CAPRA-S 52.5 72.67 20.39 91.98
BCR within 1.5 years
38G 77.78 35.17 9.01 95.04
CAPRA-S 52 71.43 12.62 94.94
BCR within 3 years
38G 81.58 36.08 13.3 89.27
CAPRA-S 51.43 72.13 17.48 92.83
BCR within 5 years
38G 80.95 36.22 14.59 93.39
CAPRA-S 53.85 72.76 20.39 92.41
BCR within 7 years
38G 81.4 36.33 15.02 93.39
CAPRA-S 52.5 72.67 20.39 91.98